| Old Articles: <Older 4901-4910 Newer> |
|---|
 |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?   |
The Motley Fool
June 11, 2008
Brian Orelli |
Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
The Motley Fool
June 10, 2008
Brian Orelli |
Third Wave's Invader Gets Invaded Hologic picks up a promising technology as the diagnostic-testing market picks up steam. |
The Motley Fool
June 10, 2008
Brian Lawler |
Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies. |
The Motley Fool
June 10, 2008
Brian Lawler |
Exelixis Secures Its Future In one of the more complicated financing deals ever made by a development-stage drugmaker, Exelixis brings in enough cash to keep guiding its lead drugs closer to market. |
The Motley Fool
June 10, 2008
Brian Lawler |
Buy Back Shares, Then Issue More? Investors marvel at what seems like temporary financial schizophrenia from American Oriental Bioengineering. |
The Motley Fool
June 9, 2008
Brian Orelli |
Treading on a Johnson & Johnson Product Johnson & Johnson's Regranex, a drug for foot ulcers, gets a warning label. |
The Motley Fool
June 9, 2008
Brian Lawler |
Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note. |
The Motley Fool
June 6, 2008
Brian Lawler |
Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects. |
| <Older 4901-4910 Newer> Return to current articles. |
